Few & Far Between: How Biotech Gets Built

Today on the Biorasi Few & Far Between Podcast:

Host Melissa Alesse welcomes Jason Tardio, President and COO of Immunic Therapeutics, to the podcast to explore the biotech journey to R&D and commercialization.

We'll also look into Immunic's novel treatments for multiple sclerosis, true team accountability, what makes biotech and big pharma so different.

Watch this episode today!

Today on the Biorasi Few & Far Between podcast:

Host Melissa Alesse welcomes Isaac Stoner, CEO of MindImmune Therapeutics, back to the podcast for a conversation on the evolving science of Alzheimer's disease and the challenges of biotech leadership.

We'll explore Alzheimer's through the lens of the immune system, discuss drug development from the perspective of investors and operators, and dive into the power of networking in Boston's biotech ecosystem. And be sure to stick around for our lightning round - quick answers to important questions.

Watch this episode today!

Today on the Biorasi Few & Far Between podcast:

What's trending in the CRO market? Find out as host Melissa Alesse welcomes Joel White, owner of Marketcap Consulting and 20+ year veteran of the CRO industry.

We'll uncover the latest in CRO strategy, biotech funding, and clinical trial program pricing. And be sure to stick around for our lightning round - quick answers to important questions.

Watch this episode today!

Today on the Biorasi Few & Far Between podcast:

Join new host Melissa Alesse and former host Chris O'Brien - CEO at Rancho BioSciences and Biorasi Board member - as they explore the origins and evolution of our podcast and what we've learned along the way.

We dive deep into the importance of long-form media and thought leadership, AI's continuous evolution, and CROs from the CEO's POV.

Watch this episode today!

Today on the Biorasi podcast, we look back on three years of AI innovation in healthcare and clinical trials - breaking new boundaries and a creating a new reality across all industries.

Host Chris O'Brien welcomes back Zak Kohane, AI Oracle and Professor and Chair of Biomedical Informatics at Harvard Medical School. We'll journey back to Zak's first appearance on the podcast and take stock of what three years means to AI development including widespread adoption by patients and physicians, how cancer still outsmarts today's LLMs, and the importance of sharing prompts with fellow AI travellers.

Find answers to the top AI questions in this new episode!

How do today’s CEOs and founders find the balance between planning and entrepreneurship?

Check out the latest episode of the Biorasi Few & Far Between podcast - How Biotech Gets Built. Host Chris O'Brien welcomes Sinan Gölhan, CEO at GelTech Labs. We'll be exploring life in a biotech startup, hydrogels in lab robotics, and bringing AI into your organization.

Watch this episode today!

Let's kick off 2026 with the first Biorasi podcast episode of the year!

How do you get "Biotech Vision" to see the complete picture of your place in the industry?

Find out in the latest episode of the Few & Far Between podcast - How Biotech Gets Built. Host Chris O'Brien welcomes guest Aoife Brennan, President and CEO of Climb Bio. We'll be discussing how to leverage science and strategy, the differences between CEOs and CMOs, and how hiring an "operational penknife" is critical to new organizations.

Watch it today!

Are clinical trial protocols a true art form?

Find out in a new episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes guest Mark Ableson, founder of Ora Clinical and CRO pioneer.

We'll be discussing exploratory endpoints, what to learn from failed trails, and essential factors in choosing a clinical site location.

Listen today!

With biotech, is it the destination, the journey, or both?

Find out in a new episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes guest Amit Etkin, Founder and CEO of Alto Neuroscience and Professor of Psychiatry at Stanford University School of Medicine. We’ll be discussing placebos in psychiatry, using biomarkers for patient outcomes, and what you can and can’t do in academia and biotech.

Watch it today!

Will GLP-1's one day replace our morning coffee?

Find out in a special video episode of the Few & Far Between podcast!

Host Chris O'Brien welcomes friend of the show, Professor Justin Stebbing. In this new segment, we'll spotlight biotech trends that you need to know about - from T cells to GLP-1 - and identify which innovations are worth the hype.

Let's start the podcast!